Great Lakes Advisors LLC Cuts Stake in LivaNova PLC (NASDAQ:LIVN)

Great Lakes Advisors LLC lowered its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 3.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 279,403 shares of the company’s stock after selling 9,862 shares during the period. Great Lakes Advisors LLC owned about 0.51% of LivaNova worth $12,939,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of LIVN. Atria Investments Inc increased its stake in shares of LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock worth $297,000 after purchasing an additional 331 shares in the last quarter. State of New Jersey Common Pension Fund D increased its stake in shares of LivaNova by 38.3% during the third quarter. State of New Jersey Common Pension Fund D now owns 42,539 shares of the company’s stock worth $2,235,000 after purchasing an additional 11,782 shares in the last quarter. Entropy Technologies LP purchased a new stake in shares of LivaNova during the third quarter worth about $529,000. GSA Capital Partners LLP purchased a new stake in shares of LivaNova during the third quarter worth about $292,000. Finally, Victory Capital Management Inc. increased its stake in shares of LivaNova by 16.6% during the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock worth $49,130,000 after purchasing an additional 133,401 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

NASDAQ:LIVN opened at $39.07 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 93.02 and a beta of 1.10. The company’s 50-day moving average is $46.32 and its two-hundred day moving average is $49.18. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.47.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Needham & Company LLC dropped their price objective on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group dropped their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Finally, StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average target price of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.